By Cameron Chai
NanoViricides declared that it has been invited to be part of the TechConnect World 2011 Conferences and Expo to be held on June 13-16 in Boston, MA to elaborate on its anti-influenza drug development studies.
At this Conference, the President and Chairman of the Company, Dr. Anil R. Diwan, will talk on “Nanoviricides as Anti-Influenza Agents”. The title of the oral presentation scheduled on June 16 is “Bio Nano Materials: Novel bio nano materials and applications”
Till date, the company has conducted many anti-influenza animal efficacy studies and successfully enhanced its FluCide candidates with each efficacy study. Recently, the company has announced that its optimized FluCide drug candidates enabled a 1,000-fold decrease in the levels of fatal influenza virus present in the lungs of animals. During the 21-day study, the company observed that two of its optimized FluCide drug candidates lowered the lung viral load significantly and maintained it throughout.
Treatment using FluCide drug candidates seemed to offer protection from spread of infection, virus expansion, and cycle of infection in the lungs of animals. This explains why animals treated with FluCide during the H1N1 influenza study showed increased survival rates and protection from influenza virus tissue injury.
The company announced that its optimized FluCide drug candidates increased survival considerably and contributed more than 95% decrease in necrosis and lung inflammation. Treatment using FluCide candidates started a day after the occurrence of the initial viral infection.